Diabetes and inflammation: Fundamental aspects and clinical implications;Diabète et inflammation: aspects fondamentaux et implications cliniques

Diabetes and Metabolism

Volumn 36, Issue 5, 2010, Pages 327-338

  Garcia, C ^a   Feve, B ^b   Ferre P ^b   Halimi, S ^c   Baizri, H ^a   Bordier, L ^a   Guiu, G ^a   Dupuy, O ^a   Bauduceau, B ^a   Mayaudon, H ^a  

^a SERVICE D ENDOCRINOLOGIE   (France)

^b INSERM   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Diabetes; Endoplasmic reticulum stress; Inflammation; Innate immunity; Obesity; Review

Indexed keywords

4 PHENYLBUTYRIC ACID; ACETYLSALICYLIC ACID; ACTIVATING TRANSCRIPTION FACTOR 1; CYTOKINE; EXENDIN 4; FORSKOLIN; GLITAZONE DERIVATIVE; INITIATION FACTOR 2ALPHA; INOSITOL REQUIRING PROTEIN 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROTEIN; PROTEIN KINASE; PROTEIN KINASE LIKE ENDOPLASMIC RETICULUM KINASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; SALSALATE; TAUROURSODEOXYCHOLIC ACID; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

ADIPOSE TISSUE; BLEEDING; CARDIOVASCULAR RISK; CELL INFILTRATION; CELLULAR STRESS RESPONSE; CYTOKINE PRODUCTION; DRUG MEGADOSE; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; GLYCEMIC CONTROL; HEREDITY; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PHENOTYPE; PROGNOSIS; REVIEW; RISK FACTOR; STOMACH HEMORRHAGE; STOMACH ULCER; STRESS; UNFOLDED PROTEIN RESPONSE;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENDOPLASMIC RETICULUM; ENDOTHELIUM, VASCULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INSULIN RESISTANCE; LIFE STYLE; OBESITY; PROTEIN UNFOLDING; RISK FACTORS; TOLL-LIKE RECEPTORS;

EID: 78649442666     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.07.001     Document Type: Review

References (106)

1. Pickup J.C., Mattock M.B., Chusney G.B., Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286-1292.
2. Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med 2004, 21:203-207.
3. Wolowczuk I., Verwaerde C., Viltart O., Delanoye A., Delacre M., Pot B., et al. Feeding our immune system: impact on metabolism. Clin Dev Immunol 2008, 2008:639803.
4. Heilbronn L.K., Campbell L.B. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008, 14:1225-1230.
5. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
6. Black P.H. The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 2003, 17:350-364.
7. Fernandez-Real J.M., Pickup J.C. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2007, 19:10-16.
8. Pickup J.C., Crook M.A. Is type 2 diabetes mellitus a disease of the innate immune system?. Diabetologia 1998, 41:1241-1248.
9. Turnbaugh P.J., Ley L.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
10. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
11. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
12. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015-3025.
13. Esposito K., Ciotola M., Sasso F., Cozzolino D., Saccomanoo F., Assaloni R., et al. Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: role of tumor necrosis factor-α. Nutr Metab Cardiovasc Dis 2007, 17:274-279.
14. Kim F., Pham M., Luttrell I., Bannerman D.D., Tupper J., Thaler J., et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 2007, 100:1589-1596.
15. Kiechl S., Lorenz E., Reindl M., Wiedermann C.J., Oberhollenzer F., Bonora E., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002, 347:185-192.
16. Kolek M.J., Carlquist J.F., Muhlestein J.B., Whiting B.M., Horne B.D., Bair T.L., et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004, 148:1034-1040.
17. Curat C.A., Miranville A., Sengenès C., Diehl M., Tonus T., Busse R. From blood monocytes to adipose tissue-resident macrophages. Induction of diapedesis by human mature adipocytes. Diabetes 2004, 53:1285-1292.
18. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
19. Antuna-Puente B., Feve B., Fellahi S., Bastard J.P. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008, 34:2-11.
20. Lumeng C., Bodzin J., Saltiel A. Obesity induces phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184.
21. Cancello R., Henegar C., Viguerie N., Taleb S., Poitou C., Rouault C., et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005, 54:2277-2286.
22. Koistinen H.A., Bastard J.P., Dusserre E., Ebeling P., Zegari N., Andreelli F., et al. Subcutaneous adipose tissue expression of tumour necrosis factor-alpha is not associated with whole body insulin resistance in obese nondiabetic or in type-2 diabetic subjects. Eur J Clin Invest 2000, 30:302-310.
23. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998, 83:847-850.
24. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
25. Wellen K.E., Hotamisligil G.S. Inflammation, stress and diabetes. J Clin Invest 2005, 115:1111-1119.
26. Murano I., Barbatelli G., Parisani V., Latini C., Muzzonigro G., Castelluci M., et al. Dead adipocytes, detected as crown-like structures (CLS), are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 2008, 49:1562-1568.
27. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance and hepatic steatosis in obesity. J Clin Invest 2006, 116:1494-1505.
28. Loffreda S., Yang S.Q., Lin H.Z., Karp C.L., Brengman M.L., Wang D.J., et al. Leptin regulates proinflammatory immune responses. FASEB J 1998, 12:57-65.
29. Van Dielen F.M., Van't Veer C., Schols A.M., Soeters P.B., Buurman W.A., Greve J.W. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 2001, 25:1759-1766.
30. Farooqi I.S., Materese G., Lord G.M., Keogh J.M., Lawrence E., Agwu C., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002, 110:1093-1103.
31. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
32. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
33. Hosogai N., Fukuhara A., Oshima K., Miyata Y., Tanaka S., Segawa K., et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007, 56:901-911.
34. Ye J., Gao Z., Yin J., He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007, 293:E1118-E1128.
35. Fève B., Bastard J.P. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:305-311.
36. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11:183-190.
37. Ghanim H., Aljada A., Daoud N., Deopurkar R., Chaudhuri A., Dandona P. Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects. Diabetologia 2007, 50:278-285.
38. Esposito K., Nappo F., Marfella R., Giugliano G., Giuglialo F., Citoloa M., et al. Inflammatory cytokines concentrations are acutely increased by hyperglycaemia in humans: role of oxidative stress. Circulation 2002, 106:2067-2072.
39. Quagliaro L., Piconi L., Assaloni R., Da Ros R., Maier A., Zuodar G., et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005, 183:259-267.
40. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005, 54:1615-1625.
41. Kvasnicka T., Kvasnicka J., Ceska R., Grauova B., Vrablik M. Increasing plasma levels of soluble cell adhesion molecules (sE-Selectin, sP-Selectin and sICAM-1) in overweight adults with combined hyperlipidemia. Sb Lek 2001, 102:473-477.
42. Scheuner D., Kaufman R.J. The unfolded protein response: a pathway that links insulin demand with β-cell failure and diabetes. Endocr Rev 2008, 29:317-333.
43. Foufelle F., Ferré P. La réponse UPR, son rôle physiologique et physiopathologique. Med Sci (Paris) 2007, 23:291-296.
44. Eizirik D.L., Cardozo A.K., Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008, 29:42-61.
45. Boot-Handford R.P., Briggs M.D. The unfolded protein response and its relevance to connective tissue diseases. Cell Tissue Res 2010, 339:197-211.
46. Ron D. Proteotoxicity in the endoplasmic reticulum: lessons from the Akita diabetic mouse. J Clin Invest 2002, 109:443-445.
47. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity insulin action, and type 2 diabetes. Science 2006, 306:457-461.
48. Allagnat F., Christulia F., Ortis F., Pirot P., Lortz S., Lenzen S., et al. Sustained production of spliced X-box binding protein 1 (XBP1) induces pancreatic beta cell dysfunction and apoptosis. Diabetologia 2010, 53:1120-1130.
49. Song B., Scheuner D., Ron D., Pennathur S., Kaufman R.J. Chop deletion reduces oxidative stress, improves β cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest 2008, 118:3378-3389.
50. Ozcan L., Ergin A.S., Lu A., Chung J., Sarkar S., Nie D., et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 2009, 9:35-51.
51. Scheuner D., Ron D., Pennathur S., Kaufman R.J. CHOP deletion reduces oxidative stress, improves β cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest 2008, 118:3378-3389.
52. Cunha D.A, Hekerman P., Ladrière L., Bazarra-Castro1 A., Ortis F., Wakeham M.C., et al. Initiation and execution of lipotoxic ER stress in pancreatic β-cells. J Cell Sci 2008, 121:2308-2318.
53. Oyadomari S., Harding H.P., Zhang Y., Oyadomari M., Ron D. De-phosphorylation of translation initiation factor 2α (eIF2α) enhances glucose tolerance and attenuates hepato-steatosis in mice. Cell Metab 2008, 7:520-532.
54. Scheuner D., Song B., McEwen E., Gillespie P., Saunders T., Bonner-Weir S., et al. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell 2001, 7:1165-1176.
55. Scheuner D., Mierde D.V., Song B., Flamez D., Creemers J.W., Tsukamoto K., et al. Control of mRNA translation preserves endoplasmic reticulum function in β-cells and maintains glucose homeostasis. Nat Med 2005, 11:757-764.
56. Cnop M., Ladriere L., Hekerman P., Ortis F., Cardozo A.K., Dogusan Z., et al. Selective inhibition of Eukaryotic Translation Initiation Factor 2α Dephosphorylation potentiates fatty acid-induced endoplasmic reticulum stress and causes pancreatic β-Cell dysfunction and apoptosis. J Biol Chem 2007, 282:3989-3997.
57. Cardozo A.K., Ortis F., Storling J., Feng Y.M., Rasschaert J., Tonnesen M., et al. Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic β-cells. Diabetes 2005, 54:452-461.
58. Pirot P., Eizirik D.L., Cardozo A.K. Interferon-γ potentiates endoplasmic reticulum stress-induced death by reducing pancreatic beta cell defence mechanisms. Diabetologia 2006, 49:1229-1236.
59. Schmidt M.I., Duncan B.B., Sharrett A.R., Lindberg G., Savage P.J., Offenbacher S., et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet 1999, 353:1649-1652.
60. Duncan B.B., Schmidt M.I., Offenbacher S., Wu K.K., Savage P.J., Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults. Diabetes Care 1999, 22:767-772.
61. Meigs J.B., O'Donnell C.J., Tofler G.H., Benjamin E.J., Fox C.S., Lipinska I., et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes. The Framingham Offspring Study. Diabetes 2006, 55:530-537.
62. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-Reactive Protein, Interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
63. Thorand B., Löwel H., Schneider A., Kolb H., Meisinger C., Fröhlich M., et al. C-Reactive Protein as a predictor for incident diabetes mellitus among middle-aged men. Results from the MONICA Augsburg Cohort Study, 1984-1998. Arch Intern Med 2003, 163:93-99.
64. Thorand B., Baumert J., Kolb H., Meisinger C., Chambless L., Koenig W., et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers. Results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007, 30:854-860.
65. Thorand B., Baumert J., Döring A., Herder C., Kolb H., Rathmann W., et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006, 184:216-224.
66. Ding E.L., Song Y., Malik V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006, 295:1288-1299.
67. Snijder M.B., Dekker J.M., Visser M., Stehouwer C.D.A., Yudkin J.S., Bouter L.M., et al. Prospective relation of C-reactive protein with type 2 diabetes (Letter). Diabetes Care 2003, 26:1656-1657.
68. Doi Y., Kiyohara Y., Kubo M., Ninomiya T., Wakugawa Y., Yonemoto K., et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 2005, 28:2497-2500.
69. Li S., Shin H.J., Ding E.L., van Dam R.M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179-188.
70. Meigs J.B., Hu F.B., Rifai N., Manson J.A.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004, 291:1978-1986.
71. Goldberg R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009, 94:3171-3182.
72. Chase H.P, Cooper S., Osberg I., Stene L.C., Barriga K., Norris J., et al. Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes 2004, 53:2569-2573.
73. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
74. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
75. Pu L.J., Lu L., Xu X.W., Zhang R.Y., Zhang Q., Zhang J.S., et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006, 5:27.
76. Pu L.J., Lu L., Xu X.W., Zhang Q., Zhang R.Y., Zhang J.S., et al. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-α with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem 2007, 40:810-816.
77. Jin C., Lu L., Zhang R.Y., Zhang Q., Ding F.H., Chen Q.J., et al. Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus. Clin Chim Acta 2009, 408:45-49.
78. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004, 292:1440-1446.
79. Haffner S., Temprosa M., Crandall J., Fowler S., Goldberg R., Horton E., et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005, 54:1566-1572.
80. Camhi S.M., Stefanick M.L., Ridker P.M., Young D.R. Changes in C-reactive protein from low-fat diet and/or physical activity in men and women with and without metabolic syndrome. Metabolism 2010, 59:54-61.
81. Dandona P., Chaudhuri A., Ghanim H., Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol 2009, 53:S14-S20.
82. Ghanim H., Mohanty P., Deopurkar R., Sia C.L., Korzeniewski K., Abuaysheh S., et al. Acute modulation of Toll-like receptors by insulin. Diabetes Care 2008, 31:1827-1831.
83. Pradhan A.D., Everett B.M., Cook N.R., Rifai N., Ridker P.M. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes. The LANCET randomized trial. JAMA 2009, 302:1186-1194.
84. Ebstein W. Zur therapie des diabetes mellitus, insbesondere über die anwendung des salicylsauren natron bei demselben. Berliner Klinische Wochenschrift 1877, 24:337-340.
85. Gao Z., Zuberi A., Quon M.J., Dong Z., Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate-1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem 2003, 278:24944-24950.
86. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998, 396:77-80.
87. Hundal R.S., Petersen K.F., Mayerson A.B., Randhawa P.S., Inzucchi S., Shoelson S.E., et al. Mechanism by which high dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002, 109:1321-1326.
88. Fleischman A., Shoelson S.E., Bernier R., Goldfine A.B. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008, 3:289-294.
89. Koska J., Ortega E., Bunt J.C., Gasser A., Impson J., Hanson R.L., et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009, 52:385-393.
90. Goldfine A.B., Fonseca V., Jablonski K.A., Pyle L., Staten M.A., Shoelson S.E. TINSAL-2D (Targeting inflammation using salsalate in type 2 diabetes) study tem. Ann Intern Med 2010, 152:346-357.
91. Ehses J.A., Böni-Schnetzler, Faulenbach M., Donath N.Y. Macrophages, cytokines and β-cell death in type 2 diabetes. Biochem Soc Trans 2008, 36:340-342.
92. Donath M.Y., Böni-Schnetzler M., Ellingsgaard H., Halban P.A., Ehses J.A. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 2010, 21:261-267.
93. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., et al. Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356:1517-1526.
94. Larsen C.M., Faulenbach M., Vaag A., Ehses J.A., Donath M., Mandrup-Poulsen T. Sustained effects of Interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009, 32:1663-1668.
95. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
96. Jiang C., Ting A.T., Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
97. Pfützner A., Marx N., Lübben G., Langenfeld M., Walcher D., Konrad T., et al. Improvement in cardiovascular risk markers by pioglitazone is independent from glycemic control. Results frome the Pioneer study. J Am Coll Cardiol 2005, 45:1925-1931.
98. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. Am J Physiol Renal Physiol 2007, 292:1141-1150.
99. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
100. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008, 24:14-26.
101. Dandona P., Ghanim H., Chaudhuri A., Mohanty P. Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. J Diabetes Complications 2008, 22:62-75.
102. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
103. Ziyadeh N., McAfee A.T., Koro C., Landon J., Chan C.A. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clin Ther 2009, 31:2665-2677.
104. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
105. Cunha D.A., Ladrière L., Ortis F., Igoillo-Esteve M., Gurzov E.N., Lupi R., et al. GLP-1 agonists protect pancreatic β-cells from lipotoxic endoplasmic reticulum stress through upregulation of Bip and JunB. Diabetes 2009, 58:2851-2862.
106. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.